Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG) following the company's first full quarter of ZUNVEYL® commercialization. This period saw significant early adoption in the U.S. long-term care market and a key regulatory milestone in China. ZUNVEYL has been ordered in over 300 long-term care facilities with 65% placing repeat orders. Additionally, Alpha Cognition secured its first national Medicare Part D contract, enhancing patient access. For more details, visit newsfilecorp.com/release/177020.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。